Eli Lilly Gains on Experimental Shot, Gemini Space Station Rises, Oracle Sinks on 3Q Forecast

On this episode of Stock Movers:

- Eli Lilly (LLY) gains 2.6% as a late-stage study showed that a next-generation obesity shot helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet.

- Gemini Space Station (GEMI) rose 20% after its application for a derivatives exchange was approved by the Commodity Futures Trading Commission in a move that will allow the company to join the fast-growing field of prediction markets.

- Oracle (ORCL) sank 13% after the company forecast 3Q cloud sales growth below analyst estimates, raising concerns that supply constraints are preventing the cloud infrastructure provider from converting its large backlog to actual revenues.

See omnystudio.com/listener for privacy information.